Ruben Dario Zapata

Ruben Dario Zapata

Auto-generated profile, based on publicly available information

Ruben Dario Zapata

Department of Health Outcomes and Biomedical Informatics, College of Medicine University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2025 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
DSDanielle L. Snyder
Danielle L. Snyder
SSSilvana Sidhom
Silvana Sidhom
CCCorinne E. Chatham
Corinne E. Chatham
STSophie Georgia Tillotson
Sophie Georgia Tillotson
RZRuben D. Zapata
Ruben D. Zapata
NMNash S. Moawad
Nash S. Moawad

20 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RZRuben D. Zapata
Ruben D. Zapata
Shu HuangShu Huang
Shu Huang
EMEarl Morris
Earl Morris
CWChang Wang
Chang Wang
CHChristopher Harle
Christopher Harle
FMFrançois Modave
François Modave
Objective: This study aimed to develop and validate predictive models using electronic health records (EHR) data to determine whether hospitalized COVID-19-positive patients would be admitted to alternative medical care or discharged home. Methods: We conducted a retrospective cohort study using deidentified data from the University of Florida Health Integrated Data Repository. The study included 1,578 adult patients (≥18 years) who tested positive for COVID-19 while hospitalized, comprising 960 (60.8%) female patients with a mean (SD) age of 51.86 (18.49) years and 618 (39.2%) male patients with a mean (SD) age of 54.35 (18.48) years. Machine learning (ML) model training involved cross-validation to assess their performance in predicting patient disposition. Results: We developed and validated six supervised ML-based prediction models (logistic regression, Gaussian Naïve Bayes, k-nearest neighbors, decision trees, random forest, and support vector machine classifier) to predict patient discharge status. The models were evaluated based on the area under the receiver operating characteristic curve (ROC-AUC), precision, accuracy, F1 score, and Brier score. The random forest classifier exhibited the highest performance, achieving an accuracy of 0.84 and an AUC of 0.72. Logistic regression (accuracy: 0.85, AUC: 0.71), k-nearest neighbor (accuracy: 0.84, AUC: 0.63), decision tree (accuracy: 0.84, AUC: 0.61), Gaussian Naïve Bayes (accuracy: 0.84, AUC: 0.66), and support vector machine classifier (accuracy: 0.84, AUC: 0.67) also demonstrated valuable predictive capabilities. Significance: This study’s findings are crucial for efficiently allocating healthcare resources during pandemics like COVID-19. By harnessing ML techniques and EHR data, we can create predictive tools to identify patients at greater risk of severe symptoms based on their medical histories. The models developed here serve as a foundation for expanding the toolkit available to healthcare professionals and organizations. Additionally, explainable ML methods, such as Shapley Additive Explanations, aid in uncovering underlying data features that inform healthcare decision-making processes.

9 April 2025 in American Journal of Hypertension
Verified
Journal Article
Closed access
RZRuben D Zapata
Ruben D Zapata
TTTioluwani Tolani
Tioluwani Tolani
RRRebecca Reich
Rebecca Reich
SBSophie Beneteau
Sophie Beneteau
HAHana Ali
Hana Ali
DLDominick J Lemas
Dominick J Lemas
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal and fetal mortality worldwide. Early detection and risk stratification are critical for timely intervention to prevent severe complications such as eclampsia, stroke, and preterm delivery. However, traditional clinical methods often lack the precision needed to identify high-risk individuals effectively. Machine learning (ML) has emerged as a powerful tool, leveraging complex data to enhance prediction, diagnosis, and clinical decision-making in HDP. This review aims to systematically evaluate ML applications in HDP, highlighting trends, methodologies, and gaps to guide future research and improve maternal and fetal outcomes. METHODS: This study adheres to the PRISMA-ScR guidelines for scoping reviews, focusing on full-text, English-language publications that apply ML models to HDP. A comprehensive search across three databases captured studies involving at-risk patient populations. Data extraction followed the CHARMS checklist, summarizing study characteristics, outcomes, and ML methodologies, while also identifying gaps and opportunities for further research. RESULTS: Most studies targeted preeclampsia (n = 70, 75.27%), with limited focus on other HDP phenotypes such as gestational hypertension (n = 4, 4.3%) and postpartum hypertension (n = 1, 1.07%). Sample sizes ranged from 20 to over 700,000 participants. Studies have been increasing since 2014 emphasizing diagnosis/onset detection (n = 58, 62.37%) and risk prediction (n = 26, 27.95%). Random forest, logistic regression, decision trees, and support vector machines were the most common ML methods. Geographic analysis revealed concentration in China (n = 29, 31.18%) and North America (n = 18, 19.35%), with underrepresentation in other regions. Input data predominantly comprised demographics (n = 50, 53.76%), patient/family history (n = 43, 46.24%), and functional tests (n = 43, 46.24%), whereas omics (n = 29, 31.18%) and imaging data (n = 2, 2.15%) were infrequently used. Outcomes related to time-to-intervenes and readmission were each reported once. CONCLUSIONS: ML is increasingly applied to HDP, with significant growth in diagnostic and risk prediction models. However, geographic disparities, limited phenotype representation, and models to help intervene at critical time points throughout the perinatal lifecycle remain barriers. Notably, models addressing time-to-intervene predictions and hospital readmissions are underrepresented, highlighting critical gaps in the current literature. Addressing these limitations—by developing models to help improve the timing of medical interventions, higher risk profiling, and diverse datasets—can advance ML’s role in improving maternal and fetal outcomes and reducing mortality globally. Future research should focus on refining ML models to support clinicians and advance care for patients with HDP.

4 December 2024 in Proceedings of SPIE
Verified
Conference Paper
Open access
HSHeng Sun
Heng Sun
SJSai Manoj Jalam
Sai Manoj Jalam
HKHavish Kodali
Havish Kodali
SNSubhash Nerella
Subhash Nerella
RZRuben D. Zapata
Ruben D. Zapata
PRParisa Rashidi
Parisa Rashidi
Mobile health (mHealth) apps have gained popularity over the past decade for patient health monitoring, yet their potential for timely intervention is underutilized due to limited integration with electronic health records (EHR) systems. Current EHR systems lack real-time monitoring capabilities for symptoms, medication adherence, physical and social functions, and community integration. Existing systems typically rely on static, in-clinic measures rather than dynamic, real-time patient data. This highlights the need for automated, scalable, and human-centered platforms to integrate patient-generated health data (PGHD) within EHR. Incorporating PGHD in a user-friendly format can enhance patient symptom surveillance, ultimately improving care management and post-surgical outcomes. To address this barrier, we have developed an mHealth platform, ROAMMEHR, to capture real-time sensor data and Patient Reported Outcomes (PROs) using a smartwatch. The ROAMM-EHR platform can capture data from a consumer smartwatch, send captured data to a secure server, and display information within the Epic EHR system using a user-friendly interface, thus enabling healthcare providers to monitor post-surgical symptoms effectively.

12 May 2026 in Obesity
Verified
Journal Article
Closed access
Dominick LemasDominick Lemas
Dominick Lemas
RZRuben Zapata
Ruben Zapata
ILIsaac Loy
Isaac Loy
AMAditya Mahadevan
Aditya Mahadevan
TWTony S. Wen
Tony S. Wen
SSSteve Smith
Steve Smith

14 August 2024 in JMIR Preprints
Verified
Preprint
Open access
RZRuben Dario Zapata
Ruben Dario Zapata
AAAlejandro Albizu
Alejandro Albizu
CPCameron Perrin
Cameron Perrin
AOAndrew O‘shea
Andrew O‘shea
CHCheshire Hardcastle
Cheshire Hardcastle
JGJoseph M. Gullett
Joseph M. Gullett
BACKGROUND Mild cognitive impairment is a transitional stage between normal cognitive aging and dementia. Identifying individuals at the preMCI stage, prior to the onset of mild cognitive decline, can be pivotal for early interventions aimed to reduce the progression neurodegeneration. OBJECTIVE The objective of this study is to develop convolutional neural networks trained on fluid attenuated inversion recovery magnetic resonance imaging for classification of preMCI in an imbalanced cohort of 350 participants. METHODS A DenseNet 264 convolutional neural network was trained on an imbalanced dataset of 350 participants with a dataset split into 64%, training, 16% validation, and 20% testing sets. Training was conducted with a batch size=70, epoch=200, processing images resized to a uniform dimension of 128×128×128 voxels, and optimizer=Adam. The optimization of our network was conducted using the Adam Optimizer with a learning rate of 10-3 and a weight decay of 5-4. Data augmentation strategy included Random affine transformation, random rotation across an axis, and random Gaussian noise on each image during training. RESULTS Mean age of the participants was 71.6 (SD 5.14); the average educational attainment was 16.3 years (SD 2.39). The mean MoCA score was 26.7 (SD 1.93). Our DenseNet mode achieved R2=0.146 and RMSE=0.569. CONCLUSIONS These findings underscore the potential of brain imaging and DL to identify this at-risk population, offering a promising tool for early detection and potential personalized preventative strategies against cognitive decline. Further research is warranted to improve upon the results to validate these findings in a larger, more diverse population.